Why the study?
How do dabigatran and rivaroxaban affect routine coagulation assays across different reagents and instruments?
How do dabigatran and rivaroxaban affect routine coagulation assays across different reagents and instruments?
Dabigatran and rivaroxaban affect routine coagulation assays in a reagent- and instrument-dependent manner, which can lead to false estimations of fibrinogen and antithrombin levels.
No takes yet. Share an insight, caveat, or question.
Potential for erroneous fibrinogen/antithrombin estimates warrants assay caution with NOACs; leaves open human reagent-specific validation.
Bailleul et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: